Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Store-brand Pepcid

This article was originally published in The Tan Sheet

Executive Summary

FDA approves abbreviated new drug applications from Perrigo and Leiner Health Products' development partner, Dr. Reddy's Laboratories, for OTC versions of famotidine 20 mg acid indigestion treatment (Johnson & Johnson-Merck's Pepcid AC). The FDA approval on Sept. 25 for private label versions of the heartburn drug comes two days after Merck's exclusivity for the product expired. Both companies began shipping the product to retail outlets immediately following the approvals. Annual Pepcid AC sales total approximately $60 mil., according to Perrigo...
Advertisement

Related Content

Patent Case Ruling Allows For Launch Of Generic Pepcid Complete

Topics

Advertisement
UsernamePublicRestriction

Register

PS099811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel